Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hiromitsu Kitanaka"'
Autor:
Hiromitsu Kitanaka, Masa-aki Sasano, Satoru Yokoyama, Masahiro Suzuki, Wanchun Jin, Masami Inayoshi, Mitsuhiro Hori, Jun-ichi Wachino, Kouji Kimura, Keiko Yamada, Yoshichika Arakawa
Publikováno v:
Emerging Infectious Diseases, Vol 20, Iss 9, Pp 1574-1576 (2014)
Externí odkaz:
https://doaj.org/article/38113a067021454bb553528c6592f7b5
Autor:
Kazuki Kitaoka, Hiromitsu Kitanaka, Yoshichika Arakawa, Jun-ichi Wachino, Wanchun Jin, Kouji Kimura, Hirotsugu Banno
Publikováno v:
Antimicrobial agents and chemotherapy. 62(8)
The prevalence of β-lactamase-negative ampicillin-resistant (BLNAR) Haemophilus influenzae has become a clinical concern. In BLNAR isolates, amino acid substitutions in penicillin-binding protein 3 (PBP3) are relevant to the β-lactam resistance. Ca
Autor:
Masahiro Suzuki, Kouji Kimura, Hiromitsu Kitanaka, Keiko Yamada, Masami Inayoshi, Yoshichika Arakawa, Masa Aki Sasano, Jun-ichi Wachino, Wanchun Jin, Mitsuhiro Hori, Satoru Yokoyama
Publikováno v:
Emerging Infectious Diseases, Vol 20, Iss 9, Pp 1574-1576 (2014)
Emerging Infectious Diseases
Emerging Infectious Diseases
To the Editor: Infections caused by Acinetobacter spp., especially A. baumannii, have been increasingly documented in recent years. Carbapenems tend to be empirically prescribed as first-choice drugs for severe invasive infections caused by Acinetoba
Autor:
Hirotsugu Banno, Hiromitsu Kitanaka, Keiko Yamada, Wanchun Jin, Kouji Kimura, Yosuke Tanaka, Jun-ichi Wachino, Yoshichika Arakawa, Keigo Shibayama
Publikováno v:
Journal of Clinical Microbiology. 52:2169-2171
We isolated and characterized three multidrug-resistant clinical isolates of group B streptococci with reduced penicillin susceptibility (PRGBS) that formed small non-beta-hemolytic colonies on sheep blood agar plates but grew well on chocolate agar
Autor:
Mitsuhiro Hori, Jun-ichi Wachino, Yoshichika Arakawa, Kouji Kimura, Wanchun Jin, Masa-aki Sasano, Satoru Yokoyama, Keiko Yamada, Hiromitsu Kitanaka
Fosfomycin (FOM) is an antibiotic produced by Streptomyces fradiae ([1][1]) and was approved for clinical use in Japan in 1980. FOM blocks MurA, which mediates bacterial peptidoglycan biosynthesis in its early step, showing a broad-spectrum antimicro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea4c5941b03e02feb8e2b5f170cf381d
https://europepmc.org/articles/PMC4136070/
https://europepmc.org/articles/PMC4136070/